金吾财讯 | 安捷伦科技(A)正式宣布，已成功完成对全球临床病理学领导者 Biocare Medical 的收购。交易完成后，Biocare Medical 将正式并入安捷伦生命科学与诊断市场集团。Biocare Medical 是全球免疫组织化学(IHC)和分子病理学解决方案领域的标杆企业，主要提供用于推进癌症诊断与研究的自动化仪器、高质量试剂及多重检测技术。此次收购被视为安捷伦在病理学产品组合上的自然战略扩张。从财务角度来看，安捷伦对此次收购的整合前景保持乐观预期。公司预计，这项并购将在第一年内直接提升安捷伦的营收增长率、利润率以及非仪器收入占比，并有望在交易完成后的12个月内实现对每股收益(EPS)的增厚。至于该项收购对安捷伦2026财年财务业绩的具体预期影响，官方透露将在即将发布的第三季度财报中作详细披露。在这笔交易中，巴克莱银行与苏利文·克伦威尔律师事务所分别担任安捷伦的财务和法律顾问；Biocare 方面则由 Jefferies 担任独家财务顾问，Ropes & Gray LLP 提供法律支持。此次强强联手，标志着安捷伦在数字化病理学平台及高精度癌症染色诊断领域，迈出了关键的一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.